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INTRODUCTION  
  
Pain is an unpleasant subjective sensation which can only be 
experienced and not expressed, especially in children. The primary reason to 
treat or prevent pain is humanitarian.  This is even more important in children 
who rely completely on their parents or care givers for their well being.  The 
concept of postoperative pain relief and its utilization in the paediatric age 
group has improved dramatically over the recent years.  
 The various methods of providing pain relief have some side effects 
which prohibit their use in children for eg, narcotics in children, because of 
their respiratory depression, the other analgesics which cannot be given for 
sometime after general anaesthesia due to the fear of vomiting and aspiration, 
the objection to the needles in the case of parenterally administered 
analgesics. 
 The regional anaesthetic techniques significantly decrease post 
operative pain and systemic analgesic requirements. Caudal route was 
chosen for this study as it is one of the simplest and safest techniques in 
paediatric surgery with a high success rate. Epidural space in children favours 
rapid longitudinal spread of drugs and makes it effective in treating 
postoperative pain. 
 Caudal block is usually placed after the induction of general anesthesia 
and is used as an adjunct to intraoperative anesthesia as well as 
postoperative analgesia in children undergoing surgical procedures below the 
level of the umbilicus1. Caudal analgesia can reduce the amount of inhaled 
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and IV anesthetic administration, attenuates the stress response to surgery, 
facilitates a rapid, smooth recovery, and provides good immediate 
postoperative analgesia1. In order to decrease intra operative and 
postoperative analgesic requirements after single shot caudal epidural 
blockade, various additives, such as morphine, fentanyl, clonidine and 
ketamine with local anaesthetics have been investigated2.   
Ropivacaine, a long-acting amide local anesthetic related structurally to 
bupivacaine, has been used for pediatric caudal anesthesia. It provides pain 
relief with less motor blockade. Literature suggests that ropivacaine is less 
cardiotoxic than bupivacaine, hence ropivacaine may be a more suitable 
agent for caudal epidural analgesia especially in day care surgery3.  
Dexmedetomidine is an α2 agonist. It has an eight-fold greater affinity 
for α2 adrenergic receptors than clonidine and much less α1 effects. A major 
advantage of dexmedetomidine is its higher selectivity compared with 
clonidine for α2A receptors which is responsible for the hypnotic and analgesic 
effects4.  
The objective of this study is to compare the analgesic effects and 
other effects of Dexmedetomidine when added to Ropivacaine for caudal 
analgesia in children undergoing lower abdominal surgeries. 
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AIM OF THE STUDY 
 
1. To compare the effects of caudal Ropivacaine and Ropivacaine 
with Dexmedetomidine in providing post operative pain relief in 
children. 
2. To study the other effects of caudal Dexmedetomidine  
3. To establish the safety of caudal dexmedetomidine in paediatric 
population.   
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REVIEW OF LITERATURE 
 
A.M.El-Hennawy et al4 compared the analgesic effects and side-
effects of Dexmedetomidine and clonidine added to bupivacaine in paediatric 
patients undergoing lower abdominal surgeries and concluded that addition of 
dexmedetomidine or clonidine to caudal bupivacaine significantly prolonged 
the duration of analgesia in children undergoing lower abdominal surgeries. 
Mausumi neogi et al5 did a comparative study between clonidine and 
dexmedetomidine used as adjuncts to ropivacaine for caudal analgesia in 
paediatric patients and concluded that addition of both clonidine and 
dexmedetomidine with ropivacaine administered caudally significantly 
increased the duration of analgesia. 
Saadawy et al6 studied the effect of dexmedetomidine on the 
characteristics of bupivacaine in caudal block in children and concluded that 
caudal dexmedetomidine provides excellent analgesia over a 24hr period 
without side effects. 
G.Ivani et al7 studied ropivacaine with clonidine combination for caudal 
blockade in children and concluded that the combination of clonidine 2mic/kg 
and ropivacaine 0.1% was associated with an improved quality of post 
operative analgesia compared to plain 0.2% ropivacaine without any 
significant post operative sedation.    
Obayah et al8 evaluated the efficacy of adding dexmedetomidine to 
bupivacaine on the duration of post operative analgesia in children who 
underwent cleft palate repair and concluded that addition of dexmedetomidine 
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to bupivacaine for greater palatine nerve  block prolongs the post operative 
analgesia after cleft palate repair with clinically no relevant side effects.  
Thomas R.Vetter et al9 studied a comparison of single dose caudal 
clonidine, morphine or hydromorphone combined with ropivacaine in 
paediatric patients undergoing ureteral reimplantation  and concluded that the 
use of caudal clonidine may be superior to caudal opiods after paediatric 
ureteral reimplantation. 
Giovanni Cucchiaro et al10 studied the effects of clonidine on post 
operative analgesia after peripheral nerve blockade in children and concluded 
that the addition of clonidine 1mic/kg to low concentrations of ropivacaine or 
bupivacaine ( 0.1% - 0.2% ) can extend the duration of sensory block and 
analgesia time in children. 
Akbas M et al11 studied a comparison of the effects of clonidine and 
ketamine added to ropivacaine on stress hormone levels and duration of 
caudal  analgesia and concluded that caudal 0.2% ropivacaine 0.75ml/kg with 
clonidine 1mic/kg for subumblical surgery attenuates changes in 
postoperative cortisol, insulin and blood glucose response to surgery 
Sharpe et al12 studied a comparison of caudal bupivacaine alone with 
bupivacaine plus two doses of clonidine for circumcision in paediatric 
population and concluded that there was an increase in analgesic duration 
with increasing doses of clonidine administered caudally and the arousal time 
was also prolonged. 
Bock M et al13 studied a comparison of caudal clonidine and 
intravenous clonidine in the prevention of agitation after sevoflurane in 
children and found that prophylactic use of clonidine decreases the 
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sevoflurane induced agitation at a dose of 4mic/kg,  independent of the route 
of administration. 
Constant  I. et al14 evaluated the addition of clonidine or fentanyl to 
local anaesthetics on the duration of surgical anaesthesia  after single shot 
caudal block in children and concluded that the addition of clonidine or 
fentanyl to local anesthetics prolongs the duration of surgical anesthesia. 
Clonidine has some advantages over fenatnyl as it does not produce clinically 
significant side effects. 
P.A.Lonnqvist et al15 studied the pharmacokinetics after caudal block 
of ropivacaine ( 2mg/ml, 1mg/kg ) in 20 children undergoing subumblical 
surgery and concluded that ropivacaine was well tolerated and provided 
satisfactory postoperative pain relief without observable motor block. 
Alparslan Turan et al16 studied caudal ropivacaine and neostigmine in 
paediatric surgery and found that a single caudal injection of neostigmine 
when added to ropivacaine offers an advantage over ropivacaine alone for 
postoperative pain relief in children undergoing genitourinary surgery. 
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ANATOMY OF CAUDAL EPIDURAL SPACE 
The key to success in any regional technique is a clear understanding 
of the normal anatomy of the region and an appreciation of the variations that 
may be encountered normally. This is possible more relevant to the success 
of the caudal blockade than to other techniques. 
Anatomy of Sacrum 
Sacrum is a large triangular bone formed by the fusion of five sacral 
vertebrae articulating above with 5th lumbar and below with the coccyx. The 
base above has median and lateral positions. The median part represents the 
body of the 1st sacral vertebra and lateral portions, known as the alae 
represent fused costal and transverse elements. 
 
The anterior surface is concave and ridged at the sites of fusion 
between the five sacral vertebrae. Lateral to the anterior sacral foramen 
through which the primary rami of the first four sacral nerves pass. 
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The posterior surface is convex and in the midline runs a bony ridge 
called the median sacral crest with three or four, but commonly four, variably 
prominent tubercles, representing rudimentary spinous processes. 
The lamina of 5th and sometimes the 4th sacral vertebra fails to fuse in 
the midline. The deficiency thus formed is known as “SACRAL HIATUS”.  The 
lateral margins of this each space bear a prominence. “SACRAL CORNUA”  
which represents the inferior articular processes of 5th sacral vertebra. 
Sacral Canal 
 It is a prismatic cavity running throughout the length of the bone and 
following its curves.  Superiorly it is triangular in section and is continuous with 
lumbar epidural space. 
Its lower extremity is the sacral hiatus which closed by posterior 
sacrococcygeal membrane which is a continuum of ligamentum flavum.  
Fibrous bands may be present in the canal and divide the epidural space into 
loculi which prevent the spread of solution and these may account for 
occasional incomplete anaesthesia. 
Contents of Sacral Canal: 
1. The dural sac extends and ends at the lower end of 2nd sacral vertebra 
on a line joining the posterior superior iliac spine from the age of 2 years, 
compared to S3 – S4 at birth. 
2. Sacral and coccygeal nerve roots with their dorsal root ganglia. 
3. The filum terminale which is the continuation of piamater, a non nervous 
terminal filament of the spinal cord. 
4. Epidural plexus of veins formed by the lower end of vertebral veins, a 
part of valveless internal vertebral venous plexus.    
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5. Loose areolar and fatty tissue is denser in males than in females.  In 
infants, fat is gelatinous spongy and few connective tissues facilitates a 
uniform and rapid spread of local analgesic solutions. In adults it is a 
closed fibrous mesh texture. 
It has been suggested that this difference gives rise to the predictability 
of caudal local anaesthetic spread in children and its unpredictability in adults. 
Sacral Hiatus: 
This is a triangular opening in the posterior wall of the sacrum resulting 
from the failure of fusion of the laminae of the 5th sacral vertebra and usually 
part of S4. It’s apex is at the level of the spine of 4th sacral vertebra.  
The hiatus is covered by sacrococcygeal membrane and pierced by the 
coccygeal nerves 5th sacral nerve.  The posterior sacro coccygeal membrane 
may be ossified in elderly subjects and making the introduction of the caudal 
needle almost impossible. 
The distance between the sacral hiatus and dural sac may be as short 
as 10 mm in a neonate. In the presence of certain sacral malformations, this 
distance might be less and the dural sac can project even up to the level of 
sacral hiatus. 
After the age of 6-7 years, epidural fat gets denser and is surrounded 
by fibrous strands, thus reducing the uniform spread of the local analgesic 
solutions. 
The important characteristic of the caudal epidural space is that it 
communicates freely with the perineural spaces surrounding the spinal nerves 
of the lumbosacral trunk.  This has several implications. Local analgesic 
solutions injected into the caudal space diffuse widely into the perineural 
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spaces, thereby improving the quality of the neural block even when dilute 
local analgesic solutions are used.  Such a leakage into the perineural spaces 
also leads to an increase in the required volume of local anaesthetic. Spaces 
are open in children and explain why larger volumes are required in children 
as compared to adults. 
The sacrum is cartilaginous in neonates and infants and its ossification 
is completed between 25 - 30 years of age.  In the neonate, the long axis of 
the sacrum forms an acute angle with the long axis of the coccyx, thereby 
making it relatively easy to palpate the sacral cornua and hiatus. As the age 
increases, the sacrococcygeal angle also increases. Thus closing the sacral 
hiatus makes a caudal anaesthetic technique difficult after the age of 7 years. 
When local anaesthetic solution is injected into the sacral canal, it 
ascends upwards in the sacral epidural space for a distance proportional to 
the volume of solution, force of injection, amount of leakage through the eight 
sacral foraminae and the consistency of the connective tissue in the space. 
Favourable anatomical differences in paediatric age group against the adult 
are, 
1) The dorsal aspect of the sacrum is almost flat in young infants and the 
sacral hiatus is identified by the easily palpable sacral cornua which is 
larger. 
2) The epidural fat is very loose in infants and children. So the predictability 
of caudal local anesthetic spread is possible in the paediatric age group. 
3) The subcutaneous tissues are also less densely packed in infants and 
children that make the palpation of landmark easier. 
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CAUDAL ANAESTHESIA 
 
Selection of Equipment 
 Reliability of the technique and the incidence of complications largely 
depend on the characteristics of the needle used.  
 The four important characteristics of the needle 
• Bevel 
• Internal and external diameter 
• Its length 
• Presence of a stylet 
Sharp bevelled Needle: 
Advantage: Traverse easily through the tissues  
Disadvantages:   
1. Characteristic “give way” when sacrococcygeal membrane is 
punctured may not be clearly felt with sharp needles. 
2. Sharp needles have long bevel advanced further into the epidural 
space so that it lies entirely within it. 
3. Cartilaginous sacrum can be easily traversed by a sharp and long 
bevelled needle leading to rectal puncture or iliac vessel puncture.   
Straight tipped needle with a bevel of 45 – 60 degree is ideal. 
Diameter: 
Small needles may bend & break during procedure. Thin needles may 
“give way”. Puncturing cartilaginous structures give rise to inadvertant 
intraosseous injection which produces effect similar to I.V. Injection. It may 
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enter pelvic viscera and cause damage. 21 to 23 Gauge is ideal because it is 
rigid and large enough to allow reflux of blood or cerebrospinal fluid. 
Length: 
Proximity of the dural sac makes it dangerous to use very long 
needles. Distance from the skin to the epidural space is almost always less 
than 20mm even in adults. So it is not advisable to use a needle longer than 
30 mm. If needle with a stylet is used, it prevents the formation of an 
epidermoid tumour due to skin tag. 
Epidural needle with 20 to 22 gauges are employed when one intends 
to use an epidural catheter via caudal route to achieve anaesthesia at higher 
level after radiographic conformation. 
Factors determining the quality of caudal block:  
• Intensity of block achieved by type and concentration of local anaesthetic. 
• Height of block  which depends on the volume injected 
Methods for determination of the volume of Local anaesthetic: 
Formula based on weight or age: 
Armitage(1979) formula - Practically easy to apply 
High sacral      - 0.5 ml / kg 
High lumbar       - 1 ml/kg 
Thoracic level     - 1.25 ml / kg 
Sclhute – Steinberg formula (up to 8-12 years)(1977) 
0.1ml / segment / year 
< 7 years – weight best predictor 
Volume required in ml = 0.65 x number of segments to be blocked x 
body weight (kg) 
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Spiegal Formula: 
Total volume of injection (ml) = 4 + (D-15) / 2 Where D is the 
distance seperating the sacral hiatus from the spinous process of 7th cervical 
vertebra. 
Modified spiegal formula: 
 Volume of injection (ml) = 4 + (D-13) / 2 
Despite larger volumes of local anaesthetic used in children as 
compared to adults, peak plasma levels of the local anaesthetics in children 
remain far below the toxic levels in adults. 
As the child grows, space becomes less compliant and large volume 
can cause higher spread of solution and thus increasing the concentration of 
local anaesthetics in the CSF. 
Patient position: 
 Three positions are available for caudal anesthesia; 
1. Prone position - Most often chosen in adults 
2. Lateral decubitus position – This is the most commonly used position in 
paediatric age group. 
3. Knee-chest position – This is infrequently used.  
The lateral decubitus position is used in children because it is easier to 
maintain a patent airway in this position than in the prone position and the 
landmarks are more easily palpable than in adults.
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Anatomical landmarks: 
Classically hiatus is described as the inferior apex of an equilateral 
triangle formed by joining the two posterior superior iliac spines and the tip of 
coccyx. 
Intergluteal fold is not an ideal landmark because it will not always 
correspond to the midline. When the left forefinger is placed in the coccyx tip, 
then the hiatus corresponds to the second crease of the finger. Palpation of 
this membrane gives a characteristic feel of a membrane under tension 
similar to that of a fontanelle. The point of puncture is at the midpoint of this 
triangular space. 
Technique: 
 Prepare area with an antiseptic solution 
Sterile drapes are placed around the site 
Puncture the skin with the needle perpendicular and bevel parallel to 
the long fibres of the sacrococcygeal membrane. 
                     
 Once the needle crosses the sacrococcygeal membrane, a “give” is felt 
after which make an angle of 20-30 degree with the skin.  This is done to 
prevent the needle hitching against the anterior aspect of the sacrum. 
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Advance the needle 2-3 mm, not more than the line joining the posterior 
superior iliac spines as to ensure that the entire bevel is within the sacral 
canal.            
Confirmation of space: 
Whoosh test: 
 It is done by injecting air via the needle and another person should 
auscultate just proximal to the injection site. If the needle is correctly 
positioned in the caudal space, then the characteristic whoosh sound is heard 
when air is pushed. 
Swoosh test 
If the needle is correctly positioned in the caudal space, while injecting 
local anaesthetics, Swoosh sound is heard at a site just proximal to hiatus, 
It is useful in children to avoid air injection which cause a patchy block 
and a rare complication of pneumocephalus if injected in large amount of air. 
Venous air embolism can also occur. 
Other techniques commonly used to identify the space are: 
o Easy injection of drug 
o No resistance to injection 
o No subcutaneous bulge 
 
Injection of Drug: 
 After a gentle aspiration, the drug should be injected over a period of 
60-90 seconds, irrespective of the volume injected (0.023 ml – 0.033 ml / 
sec). Syringe should be repeatedly aspirated during the course of injection.  
Any change in blood pressure and heart rate should be monitored while 
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injection. Faster injection cause increased cephalad spread resulting in a high 
block and respiratory problems.  
 In accidental intravascular injection, fast injection will cause rapid 
increase in peak plasma concentration. On the other hand, too slow an 
injection increase the chances of lateralization of the block or a lower level of 
anesthesia since the drug tends to leak through the foramina or increase the 
risk of needle displacement. 
Indications: 
 It is ideal for both elective and emergency lower abdominal and lower 
limb surgeries 
Emergency  :  testicular torsion, strangulated hernia repair, paraphimosis, 
wound debridement of pelvis and lower limbs  
Elective :  Usually combined with light general anaesthesia 
   Repair of inguinal hernia, umbilical hernia and hydrocele 
   Orchidopexy, anorectal and genito urinary surgery 
   Pelvic, Hip and Lower extremity surgeries  
   Phimosis 
Contraindications: 
 Local skin infection 
 Pilonidal sinus near hiatus 
 Major sacral malformation – Meningomyelocele 
 Meningitis 
 Spinabifida occulta – Not a contraindication 
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Caution:  
 Hydrocephalus 
 Convulsion disorders 
 Vertebral osteo synthesis 
 
Complications: 
Due to errors of needle position and puncture technique: 
1. Subcutaneous injection 
2. Puncturing sacral foramen – needle may enter the 3rd or 4th foramen, 
block of only the sacral root in question. 
3. Vascular puncture – By using short bevelled needle, the incidence can 
be reduced. 
4. Dural puncture - If dura is punctured withdraw the needle immediately, 
then 2nd caudal can be attempted with caution of injecting the drug under 
low pressure. 
5. Rectal injection or intra osseous injection can occur. 
Puncture complications are more common in difficult caudal.   
Complications due to errors of injection: 
1. Intravascular injection; Since epidural veins are valveless, the intra 
vascular injection is immediately followed by convulsions, arrythmias, 
hypotension and respiratory depression. 
2. Subarachnoid space injection: It leads to total spinal anaesthesia. 
3. Hemodynamic problems: This was rare in children below 8 years, in 
the absence of intravenous or subarachnoid injection. 
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4. Complete or partial failure of the block:  Complete failure of 
block is more common after 7years of age. 
Success rate increases and failure rate decreases with experience, but the 
failure rate will never be zero even in experienced hands. 
Neurologic complications: 
Urinary retention is more common if are narcotics given via caudal 
route. The first act of micturition may be delayed but not troublesome.  
Loss of consciousness is due to very rapid injection of a large 
volume of local anaesthetics. 
Nerve lesions are rarest complication 
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PHARMACOLOGY OF DEXMEDETOMIDINE
17
 
 
 
Dexmedetomidine is an α2-agonist that received FDA approval in 1999 
for use as a short-term (less than 24 h) sedative analgesic in the intensive 
care unit. Clonidine, the prototype of α2-agonist, is widely used as an adjunct 
to anesthesia and pain medicine; however, it has been little used as a 
sedative. 
With dexmedetomidine, there are a number of reasons for the growing 
and renewed interest in the use of α2-adrenoceptors agonists as sedatives. 
Dexmedetomidine compared to Clonidine is a much more selective α2-
adrenoceptor agonist, which might permit its application in relatively high 
doses for sedation and analgesia without the unwanted vascular effects from 
activation of α1-receptors. In addition, Dexmedetomidine is a short acting drug 
than clonidine and has a reversal drug for its sedative effect, Atipamezole. 
These properties render Dexmedetomidine suitable for sedation and 
analgesia during the whole perioperative period: as premedication, as an 
anesthetic adjunct for general and regional anesthesia and as postoperative 
sedative and analgesic18. 
Physiology of α2-adrenoceptors 
α2 - receptors are found in many sites throughout the body. α2 - 
adrenoceptors are found in peripheral and central nervous systems, in 
effector organs such as the liver, kidney, pancreas, eye vascular smooth 
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muscles and platelets. Physiologic responses mediated by α2 - adrenoceptors 
vary with location and can account for the diversity of their effects. 
 
The different physiologic functions of α2 adrenoreceptors. The top panel depicts the 
three α2 receptor subtypes acting as presynaptic inhibitory feedback receptors to control the 
release of norepinephrine and epinephrine from peripheral or central adult neurons. Also, a 
negative feedback loop has been seen in the adrenal gland. Alpha2B receptors have been 
involved in the development of the placental vascular system during prenatal development. 
The lower panel lists a series of physiologic effects with its associated α2 
adrenoreceptors.(From Paris A, Tonner PH: Dexmedetomidine in anaesthesia. Curr Opin 
Anaesthesiol 18:412-418, 2005)  
 
The classification of α2 - receptors based on anatomical location is 
complicated since these receptors are found in presynaptic, postsynaptic and 
extrasynaptic locations. α2 - adrenoceptors are divided into three subtypes; 
each subtype is responsible uniquely for some of the actions of α2 - receptors.  
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α2A   - predominant subtype in CNS, is responsible for the sedative, 
analgesic and sympatholytic effect.  
α2B - found mainly in the peripheral vasculature, is responsible for the 
short-term hypertensive response. 
α2C - found in the CNS, is responsible for the anxiolytic effect
19.  
All the subtypes produce cellular action by signaling through a G-
protein which couples to effector mechanisms. This coupling appears to differ 
depending on the receptor subtype and location. The α2A-adrenoceptor 
subtype seems to couple in an inhibitory fashion to the calcium channel in the 
Locus Ceruleus of the brainstem, whereas, in the vasculature, the α2B-
adrenoceptor sub type couple in an excitatory manner to the same effector 
mechanism. 
 
Mechanism of action of Dexmedetomidine 
The mechanism of action of dexmedetomidine is unique and differs 
from the currently used sedative drugs. α2 - adrenoceptors are found in many 
sites through the CNS, however, the highest densities of α2-receptors are 
found in the Locus Ceruleus, the predominant noradrenergic nuclei of the 
brainstem and an important modulator of vigilance. Presynaptic activation of 
the α2A adrenoceptor in the Locus Ceruleus inhibits the release of 
norepinephrine (NE) and results in the sedative and hypnotic effects. In 
addition, the Locus Ceruleus is the site of origin for the descending 
medullospinal noradrenergic pathway, known to be an important modulator of 
nociceptive neurotransmission. Stimulation of the α2-adrenoceptors in this 
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area terminates the propagation of pain signals leading to analgesia. 
Postsynaptic activation of α2-adrenoceptors in the CNS results in a decrease 
in the sympathetic activity leading to hypotension and bradycardia. Also, 
activation of the α2-adrenoceptors in the CNS results in an augmentation of 
cardiac vagal activity. Combined, these effects can produce analgesia, 
sedation and anxiolysis. 
At the spinal cord, stimulation of α2-receptors at the substantia 
gelatinosa of the dorsal horn leads to inhibition of the firing of nociceptive 
neurons and inhibition of the release of substance P. Also, the α2-
adrenoceptors located at the nerve endings have a possible role in the 
analgesic mechanisms of α2-agonists by preventing NE release. The spinal 
mechanism is the principal mechanism for the analgesic action of 
Dexmedetomidine, even though there is a clear evidence for both a 
supraspinal and peripheral sites of action20. 
α2 - receptors are located on the blood vessels where they mediate 
vasoconstriction and on sympathetic terminals, where they inhibit NE release. 
The responses of activation of α2-adrenoceptors in other areas include 
contraction of vascular and other smooth muscles; decreased salivation, 
decreased secretion, and decreased bowel motility in the gastrointestinal 
tract, inhibition of renin release, increased glomerular filtration, and increased 
secretion of sodium and water in the kidney; decreased insulin release from 
the pancreas, decreased intraocular pressure, decreased platelet aggregation 
and decreased shivering threshold by 2°C18. 
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Pharmacodynamics of Dexmedetomidine 
α - adrenoceptors agonists have different α2/α1 selectivity. Clonidine, 
the first developed and the most known α2-agonist is considered as a partial 
α2-agonist since its α2/α1 selectivity is 200:1 while the α2/α1 selectivity of 
dexmedetomidine is 1620:1 and hence it is 8 times more powerful α2-
adrenoceptor agonist than clonidine and is considered as a full α2 
adrenoceptor agonist. The α2-adrenoceptor selectivity of dexmedetomidine is 
dose-dependent; at low to medium doses or at slow rates of infusion, high 
levels of α2 - adrenoceptor selectivity are observed, while high doses or rapid 
infusions of low doses are associated with both α1 and α2 activities
21. 
CNS effects 
Dexmedetomidine induced sedation qualitatively resembles normal 
sleep. The participation of non rapid eye movement sleep pathways seems to 
explain why patients who appear to be “deeply asleep” from dexmedetomidine 
are relatively easily aroused in much the same way as occurs with natural 
sleep22. This type of sedation is branded “cooperative” or “arousable”, to 
distinguish it from the sedation induced by drugs acting on the GABA system 
such as midazolam or propofol, which produce a clouding of consciousness. 
Sedation induced by dexmedetomidine is dose-dependent; however, even low 
doses might be sufficient to produce sedation.  
However, clinical studies showed that systemic administration of the α2 
-adrenoceptor agonists, dexmedetomidine and clonidine produce sedative 
and opioid-sparing effects in the perioperative setting, providing indirect 
evidence for some analgesic efficacy23,24,25, although it is difficult in this 
special setting to distinguish between sedation and analgesia as a cause for 
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this opioid-sparing effect. While the analgesic effect of systemic 
dexmedetomidine is still debatable, administration of an α2-agonist (clonidine) 
via the intrathecal or epidural route provides analgesic effects in postoperative 
pain and in neuropathic pain state without severe sedation. This effect is due 
to sparing of the supraspinal CNS sites from excessive drug exposure 
resulting in robust analgesia without heavy sedation. 
 
 
 
   
The stimulation of the locus caeruleus (LC) by dexmedetomidine (right diagram) 
releases the inhibition the LC has over the ventrolateral preoptic nucleus (VLPO). The VLPO 
subsequently releases γ-aminobutyric acid (GABA) onto the tuberomammillary nucleus 
(TMN). This inhibits the release of the arousal-promoting histamine on the cortex and 
forebrain, inducing the loss of consciousness. (from Ebert T, Maze M: Dexmedetomidine: 
Another arrow for the clinican’s quiver. Anesthesiology 101:569-570, 2004) 
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Respiratory effects 
α2 - adrenoceptors do not have an active role in the respiratory center.   
Therefore, dexmedetomidine throughout a broad range of plasma 
concentration has minimal effects on the respiratory system. Coadministration 
of dexmedetomidine with other sedatives, hypnotics or opioids is likely to 
cause additive effects. 
Cardiovascular effects 
Dexmedetomidine does not appear to have direct effects on the heart. 
In the coronary circulation, dexmedetomidine causes a dose dependent 
increase in coronary vascular resistance and oxygen extraction, but the 
supply/demand ratio is unaltered. A biphasic cardiovascular response has 
been described after the administration of dexmedetomidine. A bolus of 1 
µg/kg results in a transient increase in blood pressure (BP) and a reflex 
decrease in heart rate (HR), especially in the young healthy patients. This 
initial response is attributed to the direct effects of α2B-adrenoceptor 
stimulation of vascular smooth muscle. This response can be attenuated by a 
slow infusion over 10 min, but even at slower infusion rates, the transient 
increase in mean BP and the decrease in HR over the first 10 min is shown. 
This initial response lasts for 5 to 10 min and is followed by a decrease in BP 
of 10-20% below baseline and by stabilization of the HR below baseline 
values. Both these effects are presumably caused by an inhibition of central 
sympathetic outflow that overrides the direct effects of dexmedetomidine on 
the vasculature. Hypotension and bradycardia induced by dexmedetomidine 
are reversed by ephedrine and atropine respectively, but large doses are 
required26. Dexmedetomidine decreases the heart rate in dose-depemdent 
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mannerin children. This effect is attributed to a centrally mediated sympathetic 
withdrawal, which results in unregulated cholinergic activity. 
 
Pharmacokinetics of Dexmedetomidine 
Dexmedetomidine, an imidazole compound, is the active d-isomer of 
medetomidine. Following intravenous administration, dexmedetomidine 
exhibits the following pharmacokinetic parameters: a rapid distribution phase 
with a distribution half-life (t ½ α) of 6 min, a terminal elimination half-life (t ½ 
β) of 2 hours and a steady-state volume of distribution (Vss) of 118 liters and 
a clearance about 39L. Dexmedetomidine exhibits linear kinetics when 
infused in the dose range of 0.2-0.7 µg/kg/h for no more than 24 hours. 
Dexmedetomidine undergoes almost complete biotransformation through 
direct glucuronidation and cytochrome P450 metabolism. Metabolites of 
biotransformation are excreted in the urine (95%) and feces. It is unknown if 
they had intrinsic activity.  
The average protein binding of dexmedetomidine is 94%, with 
negligible protein binding displacement by fentanyl, digoxin, 
theophilline,lidocaine and  ketorolac. There have been no sex or age-based 
differences in the pharmacokinetics of dexmedetomidine. The dose of 
dexmedetomidine should be decreased in patients with hepatic or renal 
impairment. Dexmedetomidine does cross the placenta and should be only 
used during pregnancy if the potential benefits justify the potential risk to 
fetus. 
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Dexmedetomidine is a white powder that is freely soluble in water and 
has a pka of 7.1. It is supplied as 100 µg/ml 2 ml vial which must be diluted 
with 48 ml of 0.9% sodium chloride prior to administration. For adult patient, 
dexmedetomidine is administered by a loading infusion of 0.5-1 µg/kg over 10 
minutes, followed by a maintenance infusion of 0.2 to 0.7 µg/kg/h. The effect 
appears in 5-10 min, and is reduced in 30-60 min. The maintenance infusion 
is adjusted to achieve the desired level of sedation. 
The most frequently observed adverse events in patients receiving 
dexmedetomidine for ICU sedation include hypotension, hypertension, 
nausea, bradycardia and atrial fibrillation. Most of these events occur during 
or after the loading dose, therefore, reducing or omitting the loading dose 
could result in decreasing the incidence and severity of these adverse events. 
Appropriate patient selection for dexmedetomidine administration is 
crucial; because it decreases sympathetic nervous activity, its effects may be 
most pronounced in patients with decreased autonomic nervous system 
control such as the elderly, diabetic patients, patients with chronic 
hypertension or severe cardiac disease such as valve stenosis or 
regurgitation, advanced heart block, severe coronary artery disease or in 
patients who are already hypotensive and/or hypovolemic.  
Dexmedetomidine does not affect the synthesis, storage or metabolism 
of neurotransmitters and do not block the receptors, thus providing the 
possibility of reversing the hemodynamic effects with vasoactive drugs or the 
specific alpha2-antagonist, Atipamezole which acts by increasing the central 
turnover of norepinephrine. Its duration of action is 2 hours27. 
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Perioperative uses of dexmedetomidine 
 
I – Premedication 
Dexmedetomidine possesses anxiolytic, sedative, analgesic, 
antisialogogue and sympatholytic properties, which render it suitable as a 
premedication agent. Dexmedetomidine potentiates the anesthetic effects of 
all intraoperative anesthetics (intravenous, volatile or regional block). Bohrer28 
showed that preoperative administration of intravenous or intramuscular 
dexmedetomidine resulted in a decrease in the induction dose of thiopentone 
by up to 30%. The administration of intramuscular dexmedetomidine at a dose 
of 1 µg/kg for premedication in outpatient cataract surgery resulted in 
sedation, and decrease in intraocular pressure without significant hypotension 
or bradycardia29,30. Also the administration of dexmedetomidine for 
premedication decreases oxygen consumption intraoperatively by 8% and 
postoperatively by 17%. Indications for the use of dexmedetomidine as 
premedication include patients susceptible to preoperative and perioperative 
stress, drug addicts and alcoholics, chronic opioid users and hyertensive 
patients. 
 
II – Intraoperative uses of dexmedetomidine 
Intraoperative uses of dexmedetomidine include its use as an adjunct 
to general anesthesia, as an adjunct to regional anesthesia, in monitored 
anesthesia care (MAC) or as a sole agent for total intravenous anesthesia 
(TIVA).  
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1– Use of dexmedetomidine as adjunct to general anesthesia 
The use intraoperative dexmedetomidine may increase hemodynamic 
stability because of attenuation of the stress-induced sympathoadrenal 
responses to intubation, during surgery and during emergence from 
anesthesia. Talke31 evaluated the effects of varying plasma concentrations of 
dexmedetomidine on HR, BP and catecholamines concentrations during 
emergence from anesthesia in the setting of vascular surgery. This study 
demonstrated that dexmedetomidine attenuates the increases in heart rate 
and plasma norepinephrine levels observed during the emergence from 
anesthesia. 
Administration of intravenous dexmedetomidine produces an 
anesthetic-sparing effect. Aho32 showed 25% reduction of maintenance 
concentrations of isoflurane in patients undergoing hysterectomy. Khan found 
35%-50% reduction in isoflurane concentrations with either low or high doses 
of dexmedetomidine. Fragen33 noted 17% reduction in sevoflurane 
requirements for maintenance of anesthesia in elderly patients. In addition, 
the use of dexmedetomidine produces intraoperative and postoperative 
opioid-sparing effect. Aho24 administered dexmedetomidine at dose of 0.4 
µg/kg in patients undergoing laparoscopic tubal ligation and found a 33% 
decrease in morphine use postoperatively. 
Talke34 investigated the muscle relaxant effects of dexmedetomidine on 
the neuromuscular junction and found no clinically relevant effects. 
Dexmedetomidine reduces the vasoconstriction threshold and the shivering 
threshold and is associated with a lower incidence of shivering18. 
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2 – Use of dexmedetomidine for regional anesthesia 
The use of dexmedetomidine as adjuvant in regional anesthesia is still 
not validated. Maarouf35 explored the effect of epidural dexmedetomidine on 
the incidence of postoperative shivering in patients undergoing orthopedic 
surgery. He found that patients who received dexmedetomidine at a dose of 
100 µg added to 20 ml 0.5% bupivacaine showed lower incidence in 
postoperative shivering when compared to patients who received epidural 
bupivacaine alone (10% vs.36%). Memis36 noted that the addition of 0.5 µg/kg 
dexmedetomidine to lidocaine for intravenous regional anesthesia improves 
the quality of anesthesia and perioperative analgesia without causing side 
effects. Kanazi et al37investigated the effect of adding a small dose of 3 µg of 
intrathecal dexmedetomidine to 12 mg bupivacaine. They found a significant 
prolongation of sensory and motor block as compared to bupivacaine alone. 
In this study, the effect of 3 µg intrathecal dexmedetomidine was similar to 
that produced by the addition of 30 µg of intrathecal clonidine.  
3 – Use of dexmedetomidine in monitored anesthesia care 
Dexmedetomidine confers arousable sedation with ease of orientation, 
anxiolysis, mild analgesia, lack of respiratory depression and hemodynamic 
stability at moderate doses. These properties allow dexmedetomidine to be an 
almost ideal agent for MAC despite its lack of amnesia and poor controllability 
because of its slow onset and offset. The efficacy, side effects, and recovery 
characteristics of dexmedetomidine were compared to propofol when used for 
MAC25. This study showed that dexmedetomidine achieved similar levels of 
sedation to propofol, albeit with a slower onset and offset of sedation. Neither 
dexmedetomidine nor propofol influenced respiratory rate, but propofol 
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resulted in lower mean arterial pressure during the intraoperative period. In 
the recovery room, dexmedetomidine was associated with an analgesia-
sparing effect, slightly increased sedation, but no compromise of respiratory 
function or psychomotor responses. Dexmedetomidine in MAC was used 
successfully in many situations: when patient arousability needed to be 
preserved, as for awake craniotomy, for awake carotid endarterectomy  and 
for vitreoretinal surgey. In addition, dexmedetomidine was used for sedation in 
difficult airway patients; during fiberoptic intubation, and for sedation of a 
patient with difficult airway undergoing lumbar laminectomy surgery in the 
prone chest position under spinal anesthesia.  
4 – Use of dexmedetomidine as a sole anesthetic agent 
Ramsay38 has used dexmedetomidine as a sole anesthetic agent. The 
report describes three patients who presented for surgery with potential 
airway management challenges. Dexmedetomidine was infused in increasing 
doses (up to 10 µg/kg/h) until general anesthesia was attained. No respiratory 
depression was noted, only one patient required chin lift. Also no hypotension 
or severe bradycardia were noted. The rationale for this use of 
dexmedetomidine is based on its known properties to provide sedation, 
analgesia while avoiding respiratory depression at low doses. These effects 
were maintained at higher doses without hemodynamic instability. 
III – Use of dexmedetomidine in the postoperative period 
Dexmedetomidine special properties favour its use in recovery room. In 
addition to its sympatholytic effects, analgesic effects and decreased rate of 
shivering, the preservation of respiratory function allows the continuation of 
the dexmedetomidine infusion in the extubated, spontaneously breathing 
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patient. The possibility of ongoing sedation and sympathetic block could be 
beneficial in reducing high rates of early postoperative ischemic events in 
high-risk patients undergoing non-cardiac surgery. During emergence from 
anesthesia, dexmedetomidine reduces NE levels significantly. However, 
patients who received intraoperative dexmedetomidine needed more fluids to 
avoid hypotension, a side effect that may be unfavorable in volume-sensitive 
patients with reduced left ventricular function. In addition, care should be 
taken in patients who depend on a high level of sympathetic tone or in 
patients with reduced myocardial function who cannot tolerate the decrease in 
sympathetic tone18. Perioperative administration of dexmedetomidine could be 
beneficial in chronic opioid users and alcoholics, in high-risk patients as well 
as in cardiac patients with good to moderately decreased left ventricular 
function. 
IV – Use of Dexmedetomidine in the pediatric-age group 
Only few case reports about the use of dexmedetomidine in the 
pediatric age group are found in the literature39, 40. Tobias39 used 
dexmedetomidine for ICU sedation in a10-week old infant requiring 
mechanical ventilation and in a 14-y old patient after posterior spinal fusion for 
scoliosis. The use of dexmedetomidine at a dose of 0.25 µg/kg/hr for 24 h in 
these two cases resulted in acceptable sedation without significant 
hemodynamic changes. Dexmedetomidine was also used for sedation and 
anesthesia in an 11-y old patient undergoing gastroscopy; however, it resulted 
in insufficient sedation. Another study conducted in pediatric-age group 
explored the use of intraoperative dexmedetomidine at different doses with 
the goal of reducing the post sevoflurane agitation in children aged 1-10 y. 
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The optimal dose of dexmedetomidine was 0.3 µg/kg and its use did not result 
in adverse effects41. When compared with propofol for sedation during MRI, 
dexmedetomidine provides adequate sedation during the scan but has a 
slower recovery profile40.One of the major advantages of dexmedetomidine 
over other sedatives is its respiratory effects, which are minimal in adults and 
children. it does not lead to extreme hypoxia or hypercapnia. Indeed, 
respiratory rate, CO2 tension, and oxygen saturation are generally maintained 
during dexmedetomidine sedation in children.40  
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PHARMACOLOGY OF ROPIVACAINE 
 
Ropivacaine, a new long acting amide local anesthetic was introduced 
in 1992. It has a propyl group but bupivacaine has a butyl group on the 
piperidine nitrogen atom of the molecule which was first synthesised in 
195742. Though it has similar structure, pharmacology and pharmacokinetics 
to that of bupivacaine, Ropivacaine has lower potential for toxic effect. 
Ropivacaine is a pure (s – isomer) enantiomer. On mg basis ropivacaine 
shows greater selectivity for sensory blockade and a lower systemic toxicity 
as compared to bupivacaine. 
Chemical name:  (S) – 1 propyl 2’,6’ pipecoloxylidide hydrochloride 
monohydrate 
 
 
 
Formula               :  C17H26N2O                
 
Physicochemical properties:  
Molecular mass                    :   274.4gm/mol 
pKa                                       :   8.1  
Solubility in water at 250C    :   53.8g/L 
Protein binding                     :   94% 
Volume of distribution          :   41 L 
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Mechanism of action 
 Ropivacaine reversibly interferes with the entry of sodium ion to the 
nerve cell membranes, leading to decreased membrane permeability to 
sodium and raises the threshold for electrical excitability.  The order of 
blockade affecting the nerve fibres is: autonomic, sensory and motor; and the 
effect disappears in the reverse order. Clinically the order of loss of 
sensations is: pain, temperature, touch, motor and proprioception.  
Pharmacokinetics  
It has bioavailability of about 87%- 98% when administered epidurally. 
The absorption depends on the total dose, route, concentration of the drug 
and the patients’s haemodynamic condition and the vascularity of the 
administration site. The onset of action begins at 10 – 25 min after epidural 
administration, 5min after spinal administration, 15-30 min after major nerve 
block and 1- 15 min after field block.   
Ropivacaine is extensively bound to plasma proteins (94 %), mainly α 1 
acid glycoprotein and the systemic toxicity is related to unbound drug 
concentration. It crosses the placenta. It is metabolised by Cytochrome P450 
1A by aromatic hydroxylation to 3’OH Ropivacaine and 4’OH Ropivacaine. It 
has a halflife of about 1.6 – 6hrs which varies with the route of administration. 
86% of the drug is eliminated in urine. It has greater clearance and shorter 
elimination half life as compared to bupivacaine. It also has decreased lipid 
solubility and decreased Vd as compared to bupivacaine. 
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Uses 
Ropivacaine is indicated for local anaesthesia including infiltration, 
nerve block, epidural and intrathecal anaesthesia in adults and childrens. It is 
also indicated for peripheral nerve block and caudal epidural in children for 
surgical pain. It is also sometimes used for infiltration anaesthesia for surgical 
pain in children. 
Adverse effects 
       Mostly they are related to administration technique, resulting in 
systemic exposure or pharmacological effects of anaesthesia. Allergic 
reactions can also occur. Systemic exposure to excessive quantities of 
ropivacaine mainly results in CNS and CVS effects. CNS effects usually occur 
at lower plasma concentration. 
CNS effects 
 It may include CNS excitation (nervousness, tingling around the 
mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by 
depression (drowsiness, loss of consciousness, respiratory depression and 
apnea).  
CVS effects 
It includes hypotension, bradycardia, arrhythmias, and/or cardiac 
arrest. Some of which may be due to hypoxemia secondary to respiratory 
depression 
As for bupivacaine, there is evidence that Intralipid a commonly 
available intravenous lipid emulsion can be effective in treating severe 
cardiotoxicity 
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EMERGENCE DELIRIUM IN CHILDREN
43 
Emergence delirium (ED) is not a new phenomenon in clinical practice. 
In the early 1960s, Eckenhoff et al44 were the first to report the signs of 
hyperexcitation in patients emerging from ether, cyclopropane, or ketamine 
anesthesia, particularly when administered for tonsillectomy, thyroidectomy, 
and circumcision. Children experienced postanesthesia agitation more often 
than adults (12%–13% vs 5.3%) 45. With the recognition of postoperative pain 
management in children and the increased use of analgesics, the incidence of 
emergence agitation (EA) was attenuated. However, with the introduction into 
clinical practice of the new short-acting, volatile anesthetics sevoflurane and 
desflurane, the problem of ED reemerged46. When children were aroused 
from anesthesia in a quiet manner, they suddenly entered, often due to an 
external stimulus, a state of excitation in which they could not be consoled by 
the usual methods47. Restless recovery from anesthesia may not only cause 
injury to the child or to the surgical site, but may also lead to the accidental 
removal of surgical dressings, IV catheters, and drains. Extra nursing care 
may often be necessary as well as supplemental sedative and/or analgesic 
medications, which may delay patient discharge from hospital. This adverse 
postanesthesia event raises the question about the “quality” of a particular 
anesthetic. Parents who witness ED in their child may worry about permanent 
sequelae.  
Sikich and Lerman48 defined ED as “a disturbance in a child’s 
awareness of and attention to his/her environment with disorientation and 
perceptual alterations including hypersensitivity to stimuli and hyperactive 
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motor behaviour in the immediate postanesthesia period.” ED usually occurs 
within the first 30 min of recovery from anesthesia, is self-limited (5–15 min), 
and often resolves spontaneously. 
The incidence of EA/ED largely depends on definition, age, anesthetic 
technique, surgical procedure, and application of adjunct medication. 
Generally, it ranges from 10% to 50%44,49,50, but may be as high as 80%51 . 
ANESTHESIA-RELATED FACTORS 
Rapid Emergence 
Postanesthesia agitation has been noted more often with the newer, 
less soluble, inhaled anesthetics, such as desflurane and sevoflurane, than 
with other volatile ones. It has been postulated that rapid awakening after the 
use of the insoluble anesthetics may initiate EA/ED by worsening a child’s 
underlying sense of apprehension when finding himself in an unfamiliar 
environment. Some parents claim the patient’s behaviour upon emergence 
was the same as when he was suddenly awakened from deep sleep47. Older 
children and adults usually become oriented rapidly, whereas preschool-aged 
children, who are less able to cope with environmental stresses, tend to 
become agitated and delirious. However, recovery from propofol anesthesia  
is also rapid, smooth and pleasant. Several studies have shown that 
sevoflurane anesthesia is associated with a higher incidence of EA/ED 
compared with propofol52-55. Delaying emergence by a slow, stepwise 
decrease in the concentration of inspired sevoflurane at the end of surgery did 
not reduce the incidence of EA.  
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Intrinsic Characteristics of an Anesthetic 
Most authors have documented that EA/ED occurs more often after 
sevoflurane than after halothane anesthesia49. Some authors have speculated 
that two unique, intrinsic characteristics of sevoflurane might account for the 
development of EA/ED46. First, this anesthetic exerts an irritating side effect 
on the central nervous system (CNS). Second, although sevoflurane 
degradation products appear to cause no organ damage themselves, data are 
lacking on their possible interactions with other types of medications. As for 
the eventual neurotoxic influence of sevoflurane degradation products, there 
is no supporting scientific evidence.   
SURGERY-RELATED FACTORS 
Pain 
Postoperative pain has been the most confounding variable when 
assessing a child’s behavior upon emergence because of the overlapping 
clinical picture with EA/ED. Inadequate pain relief may be the cause of 
agitation, particularly after short surgical procedures for which peak effects of 
analgesics may be delayed until the child is completely awake. In several 
studies, the preemptive analgesic approach successfully reduced EA/ED, 
suggesting that pain may be its major source56. Bock et al13 studied the effect 
of clonidine on EA in 80 children aged 3–8 yr undergoing minor day-case 
surgery who were anesthetized with sevoflurane. The children received a 
caudal block for perioperative pain relief. A dose of 3µ/kg clonidine was found 
to prevent agitation whether administered IV or caudally. Other authors 
demonstrated that an IV dose of 2µ/kg clonidine was efficient under similar 
conditions51,57. Another more selective α2 receptor agonist, dexmedetomidine, 
48 
 
also reduced sevoflurane-induced EA/ED when given prophylactically41,58. On 
the other hand, post anesthesia agitation has been observed when pain was 
efficiently treated49,50,59or even when absent53. Weldon et al59 studied 80 
premedicated children aged 12 months to 6 years undergoing inguinal hernia 
repair, whose postoperative pain was managed with a preemptive caudal 
block. At 5 min after arrival in the PACU, agitation was significantly more 
frequent in sevoflurane anesthetized children compared with halothane 
anesthetized children (26% vs 6%). A higher incidence of EA was also 
recorded in patients who received sevoflurane for non painful interventions, 
such as magnetic resonance imaging scanning and eye examinations53. In 
contrast, children anesthetized with halothane and propofol for the same 
procedures, respectively, were free of agitation. These findings clearly 
suggest that EA/ED may be a clinical phenomenon that is separate from pain.  
 
Surgery Type 
Surgical procedures that involve the tonsils, thyroid, middle ear, and 
eye have been reported to have higher incidences of postoperative agitation 
and restlessness. Eckenhoff et al44 speculated that a “sense of suffocation” 
during emergence from anesthesia may contribute to EA in patients 
undergoing head and neck surgery. However, there are no supporting 
scientific data to date. 
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PATIENT-RELATED FACTORS 
Age 
Aono et al49 found that ED appeared more often with sevoflurane than 
with halothane in preschool boys aged 3–5 yr (40% vs 10%). The difference 
was not observed in the school-aged population. All children received oral 
diazepam for premedication and a caudal block for peri operative pain control. 
The authors speculated that the psychological immaturity of preschool 
children, coupled with the rapid awakening in a strange environment, may 
have been the main cause of ED. Generally, younger children are more likely 
to show altered behaviour upon recovery from anesthesia. The subpopulation 
of those aged 2–5 yr seems to be the most vulnerable as they are easily 
confused and frightened by unexpected and unpredictable experiences. In a 
recent commentary on the diagnosis of delirium in pediatric patients, Martini60 
addressed the role of brain maturation in the genesis of this phenomenon. He 
pointed out that the pediatric brain is almost a mirror image of a normal age-
related regressive process with a consequent decline in norepinephrine, 
acetylcholine, dopamine and γ amino butyric acid (GABA). Thus, the 
development of cholinergic function and the hippocampus may suggest clues 
about the relative susceptibility of younger children to delirium. 
Preoperative Anxiety 
Intense preoperative anxiety, both in children and their parents has 
been associated with an increased likelihood of restless recovery from 
anesthesia.  
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Temperament 
Children who are more emotional, more impulsive, less social and less 
adaptable to environmental changes were identified to be at risk for 
developing postanesthesia agitation. It is likely that there is some substrate 
innate to each child that will elicit, to a larger or lesser extent, a fearful 
response to outside stimuli, depending on the interaction between the child 
and the environment. This reactivity, which describes the “excitability, 
responsivity or arousability” of the child, might be the underlying substrate 
from which both preoperative anxiety and ED arise. Patient-related factors are 
an important source of variability among studies in the incidence of EA/ED as 
they are most difficult to control when investigating this phenomenon. 
 
ADJUNCT MEDICATION 
Numerous drugs, including anticholinergics, droperidol, barbiturates, 
opioids, benzodiazepines, and metoclopramide, may contribute to behavioural 
disturbances after anaesthesia. 
In summary, none of the above-discussed factors had been proven to 
be the sole underlying cause of EA/ED. However, each factor, especially 
when combined with the others, may influence the behaviour of a child 
emerging from anaesthesia. 
 
 
 
 
 
51 
 
 
PREVENTION AND TREATMENT 
Given that the EA/ED etiology is still unknown, a clear-cut strategy for 
its prevention has not been developed. Data on the possible role of 
premedication in reducing EA/ED have been conflicting. Sevoflurane at high 
concentrations has been shown to enhance and at low concentrations to 
block the GABA -A receptor-mediated inhibition of neurotransmission in the 
CNS. On the other hand, there are studies in which midazolam premedication 
did not show any benefit on the quality of recovery from anesthesia . This 
finding may possibly be the result of applying a nonspecific measuring tool or 
a provision of inadequate pain control. Benzodiazepines themselves are 
associated with paradoxical reactions and agitation that are reversed with 
flumazenil61. Furthermore, the antianalgesic effects of midazolam might 
worsen pain and increase the incidence of nonspecific agitation that 
resembles ED.  
Various preemptive analgesic approaches, including caudal block59, 
fentanyl, ketorolac, clonidine13,57 and dexmedetomidine41,58, have been 
recommended to eliminate pain as a potential source of discomfort and 
agitation. The decision of whether to treat EA/ED with additional medication 
depends upon the severity and duration of symptoms. Many studies have 
shown that EA/ED is self-limited, resolving without pharmacological 
Intervention over time16. “Rescue” medication includes analgesics, 
benzodiazepines, and hypnotics.  A single bolus dose of dexmedetomidine 
0.5µ/kg was also shown to be efficient in the PACU for ED62. 
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PAIN ASSESSMENT IN CHILDREN 
“Pain is a unique, highly subjective multidimensional experience 
encompassing many sensory & affective components". Pain assessment is 
the most important and critical component of pain management. Assessment 
and management are interrelated. If pain can be assessed accurately, 
adequate and appropriate management can be implemented.  
 
Assessing pain in children is an ever challenging as well as a difficult 
task, mainly because so far no reliable method of assessing and measuring 
child’s pain is available. Various methods available are, 
1. Physiological measures 
2. Self reporting measures 
3. Behavioral  measures 
 
Physiological measures 
Changes in pulse, blood pressure and respiration reflect autonomic 
arousal. Autonomic responses to pain and their measurement form an 
important aspect of certain pain scales. Metabolic changes cause release of 
catecholamine, growth hormone, glucagon, cortisol, aldosterone and beta 
endorphins which have been documented in infants and children following 
noxious stimulation. Only plasma cortisol have been shown to correlate with 
behavioral responses to noxious stimuli. 
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Self reporting measures 
1. VISUAL ANALOGUE SCALE: Visual analogue scale is the accepted 
and popular method of measurement of pain in adults and provides 
reproducible results in children down to an age of five years. VAS using 
10 cm length scale marked “no pain” at one end to “excruciating pain” 
at the other end with 1 mm or 1 cm segments. The child is asked to 
identify a point on the scale which corresponds to his pain. A score of 
less than 4 is no pain, less than 6 implies tolerable pain and more than 
6 means he needs medication. VAS can also be a 50 cm long, linear 
scale with no pain at one end and excruciating pain at the other end 
with no intermediate division but with descriptive red white colorings. 
2. OUCHER’S SCALE: This scale displays six photographs of a child’s 
face showing increasing levels of discomfort. This scale is based on 
the mimic, vocalization and irritability. Features characteristic of 
increasing pain are; 
a. Distortion of face such as lowering of the brow, broadening of 
the nasal root, angular and squarish mouth, tightly closed eyes 
and tightening of the jaw. 
b. Vocalization, changing from sobbing to pain cry. 
The children are asked to show the face which mimicked their 
expression 
3. THE POKER CHIP SCALE: It quantitates the child's pain by the 
number of chips (0–4), he/she selects "pieces of hurt". 
4.  Analogue Chromatic Continuous Scale (ACCS): This system is 
potentially is useful for children as young as 3 years old. Children tend 
to associate red and black colors with increased pain sensation. (The 
back is ruled for easy scoring). 
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Behavioural Observation Methods 
 
Behavioural observation methods are the primary approach to 
accessing pain information from preverbal and nonverbal children. 
Unfortunately, development of these methods lags behind self-report 
approaches. They score the behaviours which represent the reaction to 
pain and the scores are allotted according to the degree of alteration of 
a particular behaviour. The behaviours scored include vocal behaviours 
such as cry, scream, verbally expressed pain and anxiety and non 
verbal behaviours such as muscle rigidity, torso movements, leg 
movements and facial expression. 
The PBRS, CHEOPS2, 14, CHIPPS41 and TPPPS16: Pain Behavior 
Rating Scale, Children's Hospital Eastern Ontario Pain Scale, Children and 
Infants Postoperative Pain Scale and Toddler- Preschooler Postoperative 
Pain Scale are such scales. The observation in these scales has an observer 
bias. The OBJECTIVE PAIN SCALE3 measures pain as a physiological 
variable-blood pressure along with behavioral changes. This has been shown 
to be a sensitive and reliable tool in evaluating postoperative pain in children 
who are not able to verbally comment upon their pain. This takes into account 
the systolic blood pressure, cry and its response, movement, agitation and 
verbal evaluation as described by Hannallah RS. 
FLACC4, 9, 63 and CHEOPS2 are for acute procedural and postoperative 
pain; the COMFORT scale for children in intensive care and the Parents 
Postoperative Pain Measure (PPPM) for postoperative pain managed by 
parents at home64. 
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MATERIALS AND METHODS 
Study design: 
             Prospective randomized comparative observer blinded study. 
Population: 
    60 patients  
Inclusion criteria: 
 ASA I and II patients between 6 months to 6 years of age undergoing 
lower abdominal surgeries. 
Sample size;  
• Group RD (n = 30) – Caudal 0.25% Ropivacaine  1ml/kg with 
Dexmedetomidine 2mic/kg making the volume to 0.5ml 
• Group R (n = 30) – Caudal 0.25% Ropivacaine 1ml/kg + 0.5ml normal 
saline  
Exclusion criteria : 
1. Suspected coagulopathy 
2. Infection at the site of caudal block 
3. History of developmental delay 
4. Neurological diseases 
5. Skeletal deformities 
6. Allergy to local anaesthetics 
Pre operative evaluation: 
 In all children, age, I.P. No., body weight, and baseline vital parameters 
were recorded. History regarding previous anaesthesia, surgery, any 
significant medical illness, medications and allergy were recorded. Complete 
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physical examination and airway assessment were done. Following laboratory 
investigations were done: haemoglobin %, blood sugar, urea, serum 
creatinine and urine analysis. 
Study Method: 
 After getting institutional ethical committee approval and written 
informed consent from parents, the patients were randomly allocated into two 
groups. Group R (n = 30) was taken as Ropivacaine group and Group RD 
(n=30) as Dexmedetomidine group. 
 All the patients were premedicated with Inj.Atropine 0.02mg/kg i.m. 45 
min prior to anaesthesia. Induction of anaesthesia was achieved with 50% 
N20 and 8% sevoflurane in oxygen in spontaneous ventilation. Appropriate 
size LMA was inserted.  After the insertion of LMA, Sevoflurane concentration 
was reduced to 3% in 50% nitrous oxide, patients were left in spontaneous 
ventilation and a caudal block was performed in all patients according to the 
group. The inhaled concentration of sevoflurane was adjusted to achieve 
haemodynamic changes < 30% of the baseline values4. No other narcotics, 
analgesics or sedatives were used intra operatively.    
Standard monitoring was used during anaesthesia and surgery. HR, 
MAP and SpO2 were recorded before surgery and every 5min till the end of 
surgery. 
The occurrence of intraoperative hypotension requiring a fluid bolus, 
bradycardia requiring atropine and the maximum maintenance concentration 
of sevoflurane(%) were recorded.  
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Behaviour during emergence was rated on a four-point scale41, 49:  
1. Calm 
2. Not calm but could be easily calmed 
3. Not easily calmed, moderately agitated or restless 
4. Combative, excited, or disoriented.  
Using the paediatric observational FLACC pain scale with its 0 – 10 
score range, each patient’s pain intensity was assessed at the end of surgery 
and then every 4 hr for 24 hr after operation. If the FLACC pain scale was 4 or 
more, syrup paracetamol 15mg/kg was administered. The duration of 
analgesia (from the time of caudal injection to the time at which FLACC score 
4 or more) was also recorded.  Sedation score was assessed using Ramsays 
sedation scale as follows. 
1. Anxious and agitated or restless, or both  
2. Co-operative, oriented, and calm  
3. Responsive to commands only  
4. Exhibiting brisk response to light glabellar tap or loud auditory stimulus  
5. Exhibiting a sluggish response to light glabellar tap or loud auditory 
stimulus  
6. Unresponsive  
The following times were recorded:  
1. The anaesthesia time (time from induction of anesthesia to the end of 
surgery when sevoflurane discontinued). 
2. Time from caudal block to skin incision.  
3. Time from caudal block to end of surgery. 
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4. Emergence time (time from the end of surgery to opening the eyes on 
calling).  
Complications such as PONV, respiratory depression, hypotension and 
bradycardia were also noted. Respiratory depression was defined as a 
decrease in SpO2 of <95% requiring supplementary oxygen. Hypotension 
was defined as systolic arterial pressure 70 plus twice the age in years and 
associated with altered peripheral perfusion. Bradycardia was defined as 
heart rate below 80 beats/ min for ages, 1 yr and 60 beats/ min for ages 
above 1 yr. Delayed anaesthetic emergence was defined as 20 min elapsing 
from the end of surgery to exiting the operating theatre4. 
Failure of caudal block was defined as any increase in HR or MAP >20% 
than pre incision values4.  
 
STATISTICAL ANALYSIS 
Data were analysed using SPSS version 13.0 computer software. 
Numerical variables were presented as mean and standard deviation (SD) 
and categorical variables were presented as frequency (%). Student ‘t’  test 
was used for between-group comparisons between categorical variables. 
Time to first analgesic administration was analysed by the Kaplan–Meier 
survival analysis4. 
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RESULTS 
In this study, I encountered 8 failed caudal blocks. Those cases were 
eliminated from the study.  Age, weight of the children and duration of surgery 
between both the groups were comparable and were not statistically 
significant (P>0.05). 
Table 1.  Comparison of age group between both groups 
Age in 
months 
RD group R group Total 
No % No % No % 
6 – 12 5 16.7 4 13.3 9 15.0 
13 – 24 7 23.3 3 10.0 10 16.7 
25 – 36 5 16.7 3 10.0 8 13.3 
37 – 48 4 13.3 4 13.3 8 13.3 
49 – 60 2 6.7 8 26.7 10 16.7 
61 – 72 7 23.3 8 26.7 15 25.0 
Total 30 100.0 30 100.0 60 100.0 
Mean ±SD 40.7 ± 22.1 48.9 ± 21.5 44.8 ± 22.0 
Significance P > 0.05  
 
The mean age of the RD group was 40.7 ± 22.1 months and the R 
group was 48.9 ± 21.5 months. The difference between the two groups was 
not statistically significant ( P > 0.05 ). 
 
 
 
 Figure.1.Comparison of age group between both groups
 
Table. 2. Distribution of sex in 
Sex 
No 
Male 26 
Female 4 
Total 30 
 
The above table shows sex wise distribution of RD and R group. In the 
RD group 86.6% were male and the remaining 13.7% were females. But in 
the R group, all were males. Both groups were 
difference exists. 
 
between RD and R groups
RD group R group 
% No 
86.6 30 
13.7 0 
100 30 
comparable but no statistical 
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% 
100 
0 
100 
 Table. 3. Comparison of RD and R groups in respect of their weights
Weight in Kg 
No 
0 – 5 1 
6 – 10 7 
11 -15 11 
16 – 20 10 
21 – 25 1 
Total 30 
Mean ± SD 
Significance 
 
Figure 2. Comparison of weight distribution in both groups
The mean weight of the RD group was 12.2 ± 4.2 kg and R group was 
12.7 ± 3.6 kg. The difference of 
statistically significant ( t = 0.518, d.f = 58 and P > 0.05 ).
 
. 
RD group R group 
% No 
3.3 1 
23.4 6 20.0
36.7 10 33.3
33.3 13 43.4
3.3 0 
100 30 
12.2 ± 4.2 12.7  ±  3.6 
P > 0.05 
weight between the two groups was
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% 
3.3 
 
 
 
0 
100 
 
 
 not 
 Table .4. Comparison of 
variable 
RD group 
Mean S.D
Duration of 
surgery(min) 
45.3 17.1
 
Figure 3. Comparison of duration surgery between the two groups
 
The mean duration of surgery of RD group was 45.3 ± 17.1minutes and 
R group was 41.7 ± 15.3 minutes
statistically significant (P > 0.05).
 
 
duration of surgery in both groups
R group Difference 
of mean 
‘t’ 
Significance 
(p) Mean S.D 
 41.7 15.3 3.7 0.874 P > 0.05
. The difference between the means wa
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s not 
 Table 5. Comparison of type of surgery in both 
Type of surgery
Inguinal surgeries
Urological procedures
Circumscision
Urethroplasty
Others
 
Figure.4. Comparison of type of surgery between the groups.
 
The type of surgeries between the both groups was 
but not statistically significant.
 
 
 
groups 
 RD group R group 
 8 6 
 5 8 
 9 8 
 5 5 
 3 3 
also comparable 
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 Table .6. Comparison of haemodynamic variables
 
Variables 
RD group
Mean 
Pre 
operative 
PR 95.9 
MAP 75.6 
SpO2 99.5 
Intra op 
PR 91.2 
MAP 69.7 
SpO2 99.6 
Post op 
PR 89.4 
MAP 71.9 
SpO2 99.1 
 
Figure.5.Comparison of haemodynamic variables.
The pre operative, int
changes between the groups were
significant (Table 6) and therapeutic interventions were not required.
 
 
 R group Difference 
of mean 
‘ t’ 
Significance
S.D Mean S.D 
5.6 95.2 6.9 0.7 0.431 
4.3 77.7 3.9 2.1 1.947 
0.6 99.5 0.6 0 0 
6.2 93.2 6.6 2.0 1.230 
2.2 70.0 1.3 0.3 0.646 
0.5 99.6 0.5 0 0 
6.7 91.8 6.4 2.4 1.423 
1.9 72.4 1,7 0.5 0.925 
0.7 99.1 0.7 0.4 0 
 
ra operative and post operative haemodynami
 comparable and were not statistically 
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(p) 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
P > 0.05 
 
c 
 Table 7. Comparison of 
Variables 
RD group 
Mean S.D 
Emergence 
time 
5.4 1.8 
Emergence 
behaviour 
score 
1.3 0.4 
 
Figure.6.Comparison of mean emergence behaviour score
The emergence behaviour score of the RD group was 1.3±0.4 and
R group was 3.4±0.5. The difference between the means was statistically 
highly significant (P < 0.001)
and restless compared to RD group where they were calm and co operative.
 
Emergence time and Emergence behaviour score.
R group Difference 
of means 
‘ t ‘ 
Significance
Mean S.D 
4.0 1.0 1.4 3.798 P < 0.001
3.4 0.5 2.1 17.568 P < 0.001
. This means that R group children were agitated 
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(P) 
 
 
 
 
 the 
 
 Figure.7. Comparison of 
The mean emergence time of RD group was 5.4±1.8 min and the same 
to the R group was 4.0±1.0 min. The difference of mean between the two 
groups was statistically very highly significant. ( P < 0.001).  
Figure.8
 
mean emergence time. 
 
.Emergence time for all patients 
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 Table. 8. Comparison 
Time in hours 
2 hrs 
4 hrs 
6 hrs 
8 hrs 
12 hrs 
 
Figure.9. 
The difference of mean sedation score
statistically very highly significant (P < 0.001)
sedation compared to R group that mean RD group children were asleep but 
easily arousable. 
 
of mean sedation score in the post operative 
period. 
Group RD Group R 
Significance
Mean SD Mean SD 
3 0.0 2.0 0.0 P < 0.001 
3 0.0 1.6 0.5 P < 0.001 
3 0.0 1.0 0.0 P < 0.001 
2.03 0.2 1.0 0.0 P < 0.001 
1.3 0.5 1.0 0.0 P < 0.001 
Comparison of sedation score. 
 between both groups was 
. RD group had significant 
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 Figure.10.FLACC score of RD and R group children
There was a significant difference between the groups in the FLACC 
score measured 4th hourly in the post 
achieved significantly higher FLACC score compared with Group RD,
20 out of 30 children achieved a FLACC score of 4 at 6
patients in Group RD.  Whereas
16th hr of post operative period.
 
operative period. Group R patients 
th hr compared
, in group RD children had FLACC score 4 at
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 with 0 
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Table 9.Comparison of duration of analgesia 
Group 
Mean ( hr) Median ( hr ) 
Significance 
Estimate S.E CI Estimate S.E CI 
RD 14.4 0.414 
13.59 -
15.21 
14.5 0.304 
13.90 
– 
15.09  
P < 0.001 
R 5.5 0.192 
5.15 -
5.90 
5.5 0.271 
4.97 
– 
6.03 
 
The duration of postoperative analgesia recorded a median of 5.5hr 
and 95% confidence interval (CI) (4.97 – 6.03hr) in Group R compared with 
14.5hr (13. 90 – 15.09) in Groups RD, with a P-value of < 0.001. 
Figure 11. Duration of analgesia of all patients in the study. 
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 Figure 12. Kaplan
This a step line curve showing
study for the duration of analgesia in time 
analgesia time in between  3.5 hrs for 
patient who had pain score of 4 in 
between 8 hrs and 19 hrs.
 
 
 
 
 
- Meier survival curve 
 cumulative survival of  all patients in the 
in hours, with R group showing 
the first patient and 7.5 hrs for 
the ascending order.  In RD group
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the last 
, it was 
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Table.10 Postoperative complications 
 RD group R group 
PONV Nil  Nil  
Respiratory depression Nil  Nil  
Urinary retention Nil  Nil  
Hypotension   Nil  Nil  
Bradycardia  Nil  nil  
 
No episodes of clinically significant postoperative complications such 
as PONV, respiratory depression, urinary retention, pruritus, hypotension and 
bradycardia were observed. 
 
 
 
72 
 
DISCUSSION 
Motor blockade resulting from caudal block is very distressful to 
children in the postoperative period and delays hospital discharge. 
Ropivacaine in comparison to bupivacaine, has a wider margin of safety, less 
motor blockade, less cardiovascular /neurological toxicity and similar duration 
of analgesia. It can be safely used for regional anaesthesia and analgesia in 
the ambulatory setting in paediatrics.1, 2, 3, 7, 65, 66, 67  
Like clonidine68,69, dexmedetomidine also enhances the effects of local 
anaesthetics without increasing the incidence of side effects70. A major 
advantage of dexmedetomidine is its higher selectivity compared with 
clonidine for α2A receptors which is responsible for the hypnotic and analgesic 
effect. Dexmedetomidine, although currently available for i.v. use only, has 
been successfully administered epidurally for postoperative analgesia in 
humans in clinical trials.  
El-Hennawy et al4 administered dexmedetomidine and clonidine both 
in a dose of 2µg/ kg as adjuvant with 0.25% bupivacaine caudally. They found 
that duration of analgesia was significantly higher in the group receiving 
bupivacaine-dexmedetomidine mixture [median (95%confidence level): 16 
(14-18) hrs] or bupivacaine-clonidine mixture [median (95% confidence level): 
12(3-21) hrs] than the group receiving bupivacaine alone [median (95% 
confidence level): 5 (4-6) hrs]. In our study we found that ropivacaine and 
dexmedetomidine mixture had a median14.5 hrs (CI 13.90 -15.09) duration of 
analgesia than ropivacaine  alone, which had 5.5hrs( CI 4.97 -6.03) 
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Neogi M et al5 compared Clonidine 1µg/kg and Dexmedetomidine 
1µg/kg as an adjuncts to Ropivacaine 0.25% for caudal analgesia in 
paediatric patients and concluded that addition of both clonidine and 
dexmedetomidine with ropivacaine administered caudally, significantly 
increases the duration of analgesia. The patients stay haemodynamically 
stable and there are no undue side effects. The mean duration of analgesia 
was 6.32±0.46 hours in group R, 13.17±0.68 hours in group C and 
15.26±0.86 hours in group D. The prolongation of duration of analgesia was 
significant in both groups C and D in comparison to group R. The incidence of 
adverse effects was statistically insignificant between the three groups. In our 
study we found mean duration of analgesia of 5.5 hrs in Ropivacaine group 
and 14.4 hrs in dexmedetomidine group.  
Saadawy et al6 compared caudal bupivacaine 0.25% with 
dexmedetomidine 1µg/kg and caudal bupivacaine alone and showed that the 
incidence of agitation following sevoflurane anesthesia was significantly lower 
with dexmedetomidine ( P < 0.05 ); The duration of analgesia was significantly 
longer with dexmedetomidine( P < 0.001); No statistically significant difference 
in hemodynamics between both groups; Dexmedetomidine had better quality 
of sleep and a prolonged duration of sedation(P < 0.05). This study showed 
that caudal dexmedetomidine 2µg/kg with 0.25% Ropivacaine also has similar 
results like Saadawy et al. 
Emergence agitation is a frequent side effect of sevoflurane anesthesia 
in paediatric patients. There is no well defined prophylaxis or treatment, 
although the incidence of this excitatory behaviour seems to be reduced by 
the perioperative use of sedative and analgesic drugs. α 2 receptor agonists 
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may offer advantages in preventing EA because they have both analgesic and 
sedative properties.  
Bock et al.13 studied the effect of clonidine on EA in 80 children aged 
3–8 years undergoing minor day-case surgery who were anesthetized with 
sevoflurane. The children received a caudal block for perioperative pain relief. 
A dose of 3µg/kg clonidine was found to prevent agitation whether 
administered IV or caudally. In the present study using caudal 
dexmedetomidine  2µ/kg with sevoflurane anaesthesia, the emergence 
behaviour score was less. This showed that caudally administered 
dexmedetomidine prevented the emergence agitation following sevoflurane 
significantly. 
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SUMMARY 
 
 Caudal Dexmedetomidine  2µg/ kg with 0.25%Ropivacaine 1ml/kg for 
paediatric lower abdominal surgeries achieved significant post operative pain 
relief up to 15 hours. It has stable hemodynamics in the intra operative and 
post operative period. It produces less incidence of emergence agitation 
following sevoflurane anaesthesia and better acceptable sedation in the post 
operative period. No other analgesic supplementation was needed. 
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CONCLUSION 
  
This study results conclude that Caudal Dexmedetomidine 2µg/kg 
with Ropivacaine 0.25% effectively prolongs post operative analgesia. It has 
better quality of sleep and a prolonged duration of arousable sedation. It 
reduces the emergence agitation following sevoflurane anaesthesia. It 
produces stable haemodynamics and can be safely used in paediatric day 
care surgeries.  
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A comparative study of caudal Ropivacaine vs Ropivacaine with 
Dexmedetomidine for paediatric lower abdominal surgeries. 
         PROFORMA 
Name:                                                               Age:                          Sex:               wt: 
Date:                                                                 IP No :                         ASA: 
Diagnosis:  
Procedure planned: 
History :  
Investigations:  
                           Hb%                                                                    urine albumin:     
               Blood sugar:                                                                                sugar: 
                           Urea:                                                                           deposits: 
                  Creatinine: 
O/E 
               Anaemia:                                                                      activity: 
                         HR:                                                                            BP: 
Pre-med     :     Inj. Atropine 0.02mg/kg i.m. 
Induction  :    O2 / N2O / Sevoflurane 8% 
Airway       :    LMA  
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caudal block:    
             Position   :     Lt lateral 
             Needle    :     23G i.m. needle 
             Drug        :  Group R      -   0.25% Ropivacaine 1ml/kg + 0.5ml normal 
saline 
                               Group RD   -   0.25% Ropivacaine 1ml/kg    +  
Dexmedetomidine   2µg/kg in 0.5ml normal 
saline 
Parameters Monitored : 
Haemodyna
mic variables 
baselin
e 
Intra op End of 
surger
y 
5mi
n  
10mi
n 
20mi
n 
30mi
n 
40mi
n 
50mi
n 
60mi
n 
HR          
MAP          
SpO2          
Emergence behaviour score  
Haemodyna
mic variables 
  Post op 
2 hr 4 hr 6 hr 8 hr 12 hr 
HR      
MAP      
SpO2      
Sedation      
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FLACC SCORE 
                 TIME                                                2hr 4hr 8hr 12hr 16 20hr 24hr 
FACE  
0. No particular smile or expression 
1. Occasional grimace or frown, 
withdrawn, disinterested 
2.  Frequent to constant quivering chin, 
clenched jaw 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LEGS 
      0.   Normal position or relaxed 
      1.   Uneasy, restless,tense 
      2.   Kicking or legs drawn up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACTIVITY  
0. Lying quietly, normal position, moves 
easily 
1. Squirming, shifting back and forth, 
tense 
2. Arched, rigid or jerking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRY    
0. No cry ( awake or asleep ) 
1. Moans or whimpers ; occasional 
complaint 
2. Crying steadily, screams or sobs, 
frequent complains 
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CONSOLABILITY 
0. Content. Relaxed 
1. Reassured by occasional touching, 
hugging or being talked to, distractible 
2. Difficult to console or comfort 
  
 
 
 
   
 
 
 
 
 
 
 
 
                    TOTAL SCORE                                             
 
 Time 
Induction  
Caudal block  
Skin incision  
End of surgery  
Emergence  
Analgesic supplementation  
 
 
Complications :   PONV / urinary retention / pruritus / respiratory depression 
SNO NAME WEIGHT IP no
PR MAP SpO2 5MIN 10MIN 20MIN 30MIN 5MIN 10MIN 20MIN 30MIN 5MIN 10MIN 20MIN 30MIN
1 arundoss 36/M 10kg 30027 100 81 99 86 88 90 94 70 70 73 73 100 100 99 98
2 mahesh 72/M 20kg 30692 88 83 100 78 80 80 80 75 75 74 74 100 100 99 99
3 mohammed kasim 36/M 14kg 30509 96 75 100 86 88 90 92 69 69 71 71 99 100 99 100
3 dhanush 10/M 9kg 31230 104 73 100 90 92 94 94 67 67 69 69 99 100 99 100
5 azeem 48/M 15kg 31918 90 76 100 80 82 82 84 70 70 69 69 99 100 100 99
6 mahesh 72/M 15kg 34190 92 83 99 76 78 80 84 72 72 73 73 99 100 100 99
7 VIGNSEH 72/M 18kg 32404 88 73 99 74 75 77 80 67 67 69 69 100 99 100 100
8 jegannathan 48/M 10kg 32260 96 78 100 84 86 86 88 69 69 69 69 100 99 100 100
9 vasanthan 48/M 12kg 34005 104 72 100 84 84 85 86 69 69 73 73 100 100 99 100
10 sathish 60/M 16kg 34243 100 81 100 90 94 94 96 73 73 77 77 100 100 99 100
11 veni 36/F 10kg 20104 98 73 99 88 90 90 92 69 69 68 68 99 100 99 100
12 rakesh 30/M 9kg 20667 104 73 99 88 90 94 94 70 70 73 73 99 100 99 100
13 sujith 12/M 8kg 31883 110 71 99 90 92 92 94 67 67 67 67 99 100 98 100
14 kaliappan 72/M 18kg 30694 90 80 99 76 78 78 80 69 69 71 71 100 100 99 100
15 bala 8/M 4kg 29533 110 72 99 98 98 99 99 65 65 67 67 100 100 100 100
16 immanuvel 12/M 16kg 35796 100 72 98 90 92 94 94 69 69 70 70 100 100 100 99
17 vaishnavi 24/F 10kg 28410 104 73 99 96 98 98 100 69 69 70 70 100 100 100 99
18 vijaya 11/F 6.5kg 36376 110 69 99 94 94 96 98 67 67 68 68 99 99 100 99
19 vinoth 12/M 8kg 36398 108 75 100 92 94 94 96 69 69 70 70 99 100 99 99
20 dhanush 72/M 18kg 36734 90 83 100 76 78 78 84 72 72 73 73 99 100 98 99
21 vikatan 24/M 10kg 37456 102 73 100 90 92 92 96 70 70 71 71 100 100 99 100
22 vedavalli 72/F 18kg 38467 cystoscopy 90 83 100 84 86 86 88 74 74 75 75 100 99 99 100
23 sukumaran 12/M 10kg 38090 PUV fulguration 108 72 100 90 94 96 98 69 69 70 70 100 100 99 100
24 vishal 36/M 11kg 39616 circumscision 100 74 100 88 90 92 92 70 70 70 70 99 100 99 100
25 bharath 24/M 11kg 38569 urethroplasty 104 73 99 90 92 94 96 69 69 69 69 99 100 99 99
26 esakkimuthu 72/M 17kg 39001 circumscision 88 83 99 75 77 78 80 73 73 74 74 100 100 100 99
27 albert 60/M 16kg 40384 urethroplasty 96 75 100 86 88 90 92 69 69 71 71 100 99 100 99
28 david 18/M 7kg 38998 herniotomy with circum 104 73 100 88 90 94 94 70 70 73 73 100 99 100 99
29 mansiya 24/M 9kg 40527 URS 108 72 100 90 94 96 98 69 69 70 70 100 99 100 100
30 maharajan 36/M 10kg 40705 circumscision 100 74 99 88 90 92 92 70 70 70 70 100 99 100 100
RD GROUP
INTRAOP
PR MAP SpO2
TYPE of SURGERY
SSG
circumscision
hydroceleand circum
herniotomy
herniotomy
cystoscopy
circumscision
circumscision
urethroplasty
AGE/SEX
soft tissue tumour leg
hydrocele
circumscision
meataldilatation and circum
circumscision
anoplasty
PRE OP
urethroplasty
PUV fulguration
hernitomy
hydrocele
hydrocele
urethroplasty
DOS
emergence 
time
emergence 
behaviour
Score
EOS
PR MAP SpO2 2 4 6 8 12 2 4 6 8 12 2 4 6 8 12
86 70 97 40min 5min 1 86 88 90 94 94 90/60 70 96/62 73 98/62 74 100/60 73 100/60 73 99 99 97 99 100
78 75 98 40min 5min 1 78 80 80 80 80 100/62 75 102/60 74 102/62 75 104/62 76 104/68 80 99 99 98 99 100
86 69 98 95min 7min 2 86 88 90 92 92 90/58 69 94/60 71 96/60 72 96/62 73 100/60 73 99 98 98 99 100
90 67 99 40min 4min 1 90 92 94 94 94 90/56 67 92/58 69 92/60 71 92/62 73 92/60 71 99 98 99 99 99
80 70 100 60min 5min 2 80 82 82 84 84 90/60 70 92/60 69 92/60 71 92/62 73 92/64 73 99 97 100 99 99
76 72 100 40min 6min 1 76 78 80 84 84 96/60 72 96/62 73 98/62 74 100/62 75 100/62 75 100 100 100 100 98
74 67 99 35min 7min 1 74 75 77 80 80 90/56 67 90/58 69 92/60 71 94/60 71 94/60 71 99 99 99 99 99
84 69 98 60min 9min 2 84 86 86 88 90 90/58 69 92/60 69 92/60 71 94/60 71 94/60 71 99 99 98 99 99
84 69 99 45min 5min 1 84 84 85 86 88 92/60 69 92/62 73 94/60 71 98/60 73 100/60 73 99 100 99 99 99
90 73 99 40min 6min 2 90 94 94 96 98 100/60 73 104/64 77 104/62 76 102/70 81 104/70 81 99 98 99 99 99
88 69 99 80min 11MIN 2 88 90 90 92 93 88/56 69 88/58 68 90/58 69 90/58 69 90/60 70 100 99 99 100 99
88 70 99 45min 6min 1 88 90 94 94 96 90/60 70 94/62 73 98/60 73 98/60 73 98/60 73 100 99 99 100 100
90 67 97 30min 4min 1 90 92 92 94 96 86/58 67 88/56 67 88/60 69 90/60 70 90/60 70 100 99 97 100 100
76 69 98 40min 5min 1 76 78 78 80 84 92/60 69 94/60 71 98/62 74 100/60 73 102/60 74 100 99 98 100 100
98 65 99 30min 3min 1 98 98 99 99 100 88/54 65 88/56 67 90/58 69 90/58 69 92/60 71 100 99 99 100 99
90 69 99 35min 3min 1 90 92 94 94 96 90/58 69 90/60 70 92/60 71 94/60 71 94/60 71 99 100 99 99 99
96 69 100 40min 4min 1 96 98 98 100 102 92/58 69 90/60 70 92/60 71 94/60 71 96/60 72 99 100 100 99 98
94 67 100 35min 3min 1 94 94 96 98 105 86/58 67 88/58 68 88/60 69 90/58 69 90/58 69 99 100 100 99 98
92 69 100 35min 3min 1 92 94 94 96 98 90/58 69 90/60 70 92/60 71 94/60 71 94/60 71 99 100 100 99 100
76 72 100 40min 5min 1 76 78 78 84 84 96/60 72 98/60 73 100/60 73 100/62 75 106/60 75 100 99 100 100 100
90 70 99 45min 5min 1 90 92 92 96 98 90/60 70 92/60 71 94/60 71 94/60 71 94/60 71 99 99 99 99 99
84 74 98 40min 6min 1 84 86 86 88 88 98/62 74 98/64 75 100/64 75 100/66 77 100/70 80 100 99 98 100 99
90 69 97 45min 4min 1 90 94 96 98 100 90/58 69 90/60 70 92/60 71 92/60 71 94/60 71 99 98 97 99 99
88 70 97 30min 6min 1 88 90 92 92 94 94/58 70 94/58 70 96/60 72 98/60 73 98/60 73 99 99 97 99 99
90 69 98 50min 7min 2 90 92 94 96 98 90/58 69 92/58 69 92/60 71 92/60 71 94/60 71 100 99 98 100 100
75 73 99 30min 5min 1 75 77 78 80 80 100/60 73 102/60 74 102/62 75 104/60 73 104/60 73 100 99 99 100 100
86 69 100 95min 7min 2 86 88 90 92 92 90/58 69 94/60 71 96/60 72 96/62 73 100/60 73 99 99 100 99 100
88 70 100 45min 6min 1 88 90 94 94 96 90/60 70 94/62 73 98/60 73 98/60 73 98/60 73 99 100 100 99 100
90 69 97 45min 4min 2 90 94 96 98 100 90/58 69 90/60 70 92/60 71 92/60 71 94/60 71 99 100 97 99 99
88 70 98 30min 6min 1 88 90 92 92 94 94/58 70 94/58 70 96/60 72 98/60 73 98/60 73 98 99 98 98 99
RD GROUP
POST OPERETIVE PERIOD (HOURS)
PR SpO2MAP
Total 
duration 
of analgesia 
hrs
2 4 6 8 12 2 4 6 8 12 16 20 24
3 3 2 2 2 0 0 0 1 1 3 4 18
3 3 2 2 2 0 1 2 2 3 4 14
3 3 2 2 2 0 0 0 1 3 4 15
3 3 2 2 2 0 1 2 4 8
3 3 2 2 2 0 2 2 3 3 4 13
3 3 2 2 1 0 0 0 1 3 4 15
3 3 2 3 1 0 0 0 1 2 4 14.5
3 3 2 2 1 0 2 3 4 8
3 3 2 2 1 0 0 0 1 1 4 15.5
3 3 2 2 2 0 0 0 1 1 3 4 17
3 3 2 2 2 0 0 1 1 1 4 16
3 3 2 2 1 0 0 0 1 2 4 14
3 3 2 2 1 0 0 0 1 2 4 14
3 3 2 2 1 0 0 0 1 2 4 15
3 3 2 2 1 0 0 1 1 2 4 14
3 3 2 2 1 0 0 1 2 2 4 14.5
3 3 2 2 1 0 1 2 3 4 12
3 3 2 2 1 0 0 1 2 2 4 15
3 3 2 2 1 0 0 1 2 2 4 16
3 3 2 2 2 0 0 1 2 3 4 14
3 3 2 2 2 0 1 2 2 3 4 16
3 3 2 2 1 0 0 1 2 2 3 4 19
3 3 2 2 1 0 1 2 2 3 4 14
3 3 2 2 1 0 0 1 2 3 4 13
3 3 2 2 1 0 0 1 2 3 4 14.5
3 3 2 2 1 0 1 2 3 3 4 15
3 3 2 2 1 0 0 0 2 3 4 13
3 3 2 2 1 0 0 1 3 3 4 15
3 3 2 2 2 0 1 2 3 3 4 14
3 3 2 2 1 0 0 1 3 3 4 16
RD GROUP
POST OPERETIVE PERIOD (HOURS)
SEDATION FLACC
SNO NAME AGE/SEX WEIGHT IP no TYPE OF SURGERY
PR MAP spo2
5MIN 10MIN 20MIN 30MIN 5MIN 10MIN 20MIN 30MIN 5MIN 10MIN 20MIN
1 madan gopal 72/M 15kg 34568 urethroplasty 84 81 99 76 78 79 81 75 76 77 78 98 99 100
2 sethupathy 60/M 15kg 34589 cystoscopy and circm 88 83 100 80 82 83 84 75 76 77 77 99 99 100
3 jeevanathan 12/M 10kg 33584 circumscision 104 72 100 88 90 92 96 68 66 67 69 100 99 100
4 balajothi 72/M 15kg 32934 cystoscopy 94 84 100 90 90 92 94 78 79 79 79 100 99 100
5 karthick 24/M 6kg 32430 circumscision 105 76 100 90 94 96 98 72 72 73 74 99 100 100
6 manthiramoorthy 72/M 15kg 31901 circumscision 88 83 99 80 82 86 88 79 80 81 81 99 100 100
7 ajay 72/M 15kg 31737 PUV fulguration 90 73 99 86 88 90 92 70 68 70 71 100 100 99
8 esakkimuthu 36/M 8kg 31195 hydrocele 90 83 100 90 86 86 88 78 75 74 75 100 100 99
9 tharunraj 72/M 15kg 30644 cystoscopy and biopsy 86 83 100 86 84 87 86 70 68 70 72 100 99 100
10 kavibalan 48/M 15kg 30472 PUV fulguration 100 81 100 100 98 99 96 75 74 77 78 100 99 100
11 madan kumar 7/M 4.2kg 30022 PUV fulguration 92 83 99 94 92 90 92 72 74 75 76 100 99 100
12 pathirakali 60/M 9kg 29377 urethroplasty 82 85 99 90 86 84 80 76 75 78 80 100 99 100
13 ashiq 10/M 8.5kg 35765 circumscision 98 81 99 90 92 90 90 74 76 74 77 100 98 100
14 ganeshamoorthy 60/M 14kg 29736 RA foot- flap cover 98 80 99 102 101 100 101 75 76 78 80 100 99 100
15 thirumalai 72/M 17kg 34831 urethroplasty 98 73 99 98 98 99 99 68 68 69 70 100 100 100
16 nithish kumar 36/M 8kg 36400 herniotomy 100 75 98 100 100 98 99 68 69 68 70 99 100 100
17 thayubala 10/M 8kg 36389 hydrocele 104 73 99 102 100 101 102 66 68 69 70 99 100 100
18 guna 72/M 13kg 34830 cystoscopy 96 77 99 94 92 94 94 67 68 69 70 99 100 99
19 sakthivel 72/M 17kg 36847 circumscision 94 75 100 94 92 92 94 69 70 72 72 99 99 100
20 rahul 48/M 15kg 37510 circumscision 106 73 100 106 104 106 108 69 70 71 72 99 98 100
21 poovarasan 72/M 17kg 37948 herniotomy 94 81 100 90 90 92 94 78 77 79 80 100 99 100
22 ganeshamoorthy 60/M 14kg 29736 RA foot- flap delay 98 80 100 102 101 100 101 75 72 76 77 100 99 99
23 saravanan 42/M 14kg 38598 herniotomy 90 83 100 90 86 86 88 75 76 78 78 100 99 100
24 subash chandrabose 36/M 10kg 39466 orchiopexy 104 72 100 88 90 92 96 65 67 68 69 100 99 100
25 karuppasamy 72/M 15kg 39277 urethroplasty 84 81 99 76 78 79 81 74 76 77 78 99 99 100
26 maria nishanth 36/M 12kg 37853 circumscision 104 72 99 88 90 92 96 66 65 68 69 99 100 100
27 uthandaraman 48/M 13kg 46358 cystoscopy 94 81 100 90 90 92 94 74 75 76 78 99 100 99
28 rajesh kumar 72/M 19kg 40694 herniotomy 94 81 100 90 90 92 94 74 72 77 76 99 100 99
29 abishkumar 36/M 12kg 40690 circumscision 104 72 100 88 90 92 96 65 64 67 68 100 100 99
30 esakkidurai 60/M 12.5kg 40687 rectal polyp excision 94 81 99 90 90 92 94 75 77 78 80 100 100 99
R GROUP
PREOP INTRAOP
PR MAP SpO2
30MIN
100
100
99
99
99
99
100
100
100
100
99
99
99
100
100
100
100
99
99
99
100
100
100
99
99
100
100
100
100
100
EOS DOS
Emergence
time
emergence 
behavour 
score
PR MAP SpO2 time SCORE 2 4 6 8 12 2 4 6 8 12 2 4 6 8 12
76 78 100 70min 5min 3 76 78 79 81 82 74 77 76 81 81 97 99 99 97 99
78 78 100 45min 4min 3 80 82 83 84 86 73 75 75 80 82 98 99 99 98 99
88 70 100 30min 3min 3 88 90 92 96 98 70 71 71 72 73 98 99 98 98 99
90 80 99 35min 4min 3 90 90 92 94 94 73 73 74 77 79 99 99 98 99 99
90 76 99 30min 3min 3 90 94 96 98 100 71 72 74 75 76 100 99 97 100 99
80 82 98 35min 5min 3 80 82 86 88 90 75 79 81 82 83 100 100 100 100 100
88 72 99 45min 5.5min 4 86 88 90 92 92 73 75 73 76 79 99 99 99 99 99
88 76 99 35MIN 3min 4 90 86 86 88 90 83 81 82 81 83 98 99 99 98 99
84 74 99 40MIN 4min 4 86 84 87 86 85 79 81 83 83 83 99 99 100 99 99
90 80 99 45MIN 3min 4 100 98 99 96 98 75 77 76 81 81 99 99 98 99 99
92 80 99 45MIN 5min 3 94 92 90 92 93 89 89 86 89 90 99 100 99 99 100
82 84 100 80MIN 5.5min 3 90 86 84 80 82 85 81 83 85 87 99 100 99 99 100
90 78 100 35MIN 3min 4 90 92 90 90 92 83 78 76 80 79 97 100 99 97 100
100 80 100 40MIN 4min 3 102 101 100 101 100 73 73 74 73 74 98 100 99 98 100
100 70 99 90MIN 3min 4 98 98 99 99 98 73 73 73 73 73 99 100 99 99 100
100 70 99 35MIN 5min 3 100 100 98 99 99 74 73 73 73 73 99 99 100 99 99
103 70 98 40MIN 5.5min 4 102 100 101 102 100 73 73 73 73 73 100 99 100 100 99
96 72 98 40MIN 3min 3 94 92 94 94 92 73 73 73 73 73 100 99 100 100 99
96 74 100 30MIN 4min 4 94 92 92 94 94 73 73 74 73 74 100 99 100 100 99
108 72 100 30MIN 3min 3 106 104 106 108 106 72 73 73 73 73 100 100 99 100 100
95 81 99 35min 5min 4 90 90 92 94 94 73 73 74 77 79 99 99 99 99 99
102 80 99 40MIN 5.5min 3 102 101 100 101 100 75 73 74 73 74 98 100 99 98 100
90 80 99 35MIN 3 MIN 4 90 86 86 88 90 85 81 82 81 83 97 99 98 97 99
98 70 99 30min 3min 3 88 90 92 96 98 70 71 71 72 73 97 99 99 97 99
83 79 100 70min 5min 4 76 78 79 81 82 74 77 76 81 81 98 100 99 98 100
98 70 100 30min 3min 3 88 90 92 96 98 70 71 71 72 73 99 100 99 99 100
96 78 100 35min 4min 4 90 90 92 94 94 73 73 74 77 79 100 99 99 100 99
96 79 100 35min 4min 3 90 90 92 94 94 73 73 74 77 78 100 99 100 100 99
95 69 99 30min 3min 4 88 90 92 96 98 70 71 71 72 73 97 99 100 97 99
95 81 99 35min 4min 3 90 90 92 94 94 73 73 74 77 78 98 98 99 98 98
POST OPERATIVE PERIOD (HOURS)
R GROUP
PR MAP SpO2
2 4 6 8 12 2 4 6 8 12
2 2 1 1 1 2 4 4
2 2 1 1 1 0 2 3 4 6.5
2 2 1 1 1 0 2 4 5.5
2 2 1 1 1 1 2 3 4 6.5
2 1 1 1 1 0 2 4 4.5
2 2 1 1 1 0 2 3 4 6.5
2 1 1 1 1 1 4 4
2 2 1 1 1 0 2 4 5
2 1 1 1 1 0 2 3 4 6.5
2 2 1 1 1 0 2 3 4 6.5
2 1 1 1 1 0 1 3 4 7.5
2 2 1 1 1 2 4 4
2 1 1 1 1 0 3 3 4 6.5
2 2 1 1 1 1 2 3 4 7
2 1 1 1 1 1 3 4 6
2 2 1 1 1 0 2 3 4 7
2 1 1 1 1 0 2 4 6
2 2 1 1 1 0 2 4 5.5
2 1 1 1 1 0 3 4 6
2 2 1 1 1 1 2 4 5.5
2 1 1 1 1 0 2 3 4 6.5
2 2 1 1 1 1 3 4 4.5
2 1 1 1 1 0 2 4 5
2 2 1 1 1 1 4 3.5
2 2 1 1 1 1 2 4 5.5
2 2 1 1 1 0 3 4 5
2 1 1 1 1 0 1 4 5.5
2 2 1 1 1 1 2 4 5
2 1 1 1 1 0 3 4 4.5
2 2 1 1 1 1 3 4 4.5
FLACC
Total 
duration of 
analgesia 
hrs
POST OPERATIVE PERIOD (HOURS)
R GROUP
SEDATION
